UroGen Pharma Ltd.

Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the EuroGen Pharma Q3 2023 earnings call. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Vincent Perrone, Head of Investor Relations. You may begin.

Thank you, Operator.

Good morning, everyone, and welcome to EuroGen Pharma's third quarter 2023 financial results and business update conference call. Earlier this morning, we issued our third quarter press release and filed our 10Q, where you can find details for our financial and operating results. Both documents can be accessed on the investors portion of our website at investors.eurogen.com. Joining me on the call today are Liz Barrett, President and Chief Executive Officer, Dr. Mark Schoenberg, Chief Medical Officer, Jeff Bova, Chief Commercial Officer, and Don Kim, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to gel mito, our ongoing and planned clinical trials, commercial and clinical milestones, market and revenue opportunities, our commercial strategy and expectation, as well as potential future commercialization activities for EGM-102, if approved. Anticipated data, regulatory filings, and decisions, including UGN 102, potentially receiving priority review, UGN 102 being the growth driver for Eurogen and for Proust, future research and development efforts, our corporate goals, and 2023 financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. Your caution not to place undue reliance on these forward-looking statements and your agenda's claims any obligation to update these statements. I'll now turn the call over to Liz. Liz?